News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Subscribe To Our Newsletter & Stay Updated
